Tunlametinib is under clinical development by Binjiang Pharma and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tunlametinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tunlametinib overview

Tunlametinib (Kolupin) is an antineoplastic agent. It is formulated as capsules for the oral route of administration. Kolupin is indicated for the treatment of NRAS mutated advanced melanoma who have failed PD-L1 therapy.

Tunlametinib (HL-085) is under development for the treatment of advanced solid tumors with BRAF V600 mutation, metastatic colorectal cancer, neurofibromatoses type I mutant plexiform neurofibroma, non-small cell lung cancer and NRAS mutant advanced melanoma. It is formulated as the capsule and administered through oral route. The drug candidate acts by targeting dual specificity mitogen-activated protein kinase kinase 1 (MEK1).

Binjiang Pharma overview

Binjiang Pharma is a biopharmaceutical company. It offers drug discovery, process development and customized services. The company, together with its partners develops targeted small molecule drugs, which has competitive advantages over the existing therapies. Binjiang Pharma is headquartered in Tianjin, China.

For a complete picture of Tunlametinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.